IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0213219.html
   My bibliography  Save this article

Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort

Author

Listed:
  • Ana Paula Monteiro Gomides
  • Cleandro Pires de Albuquerque
  • Ana Beatriz Vargas Santos
  • Rodrigo Balbino Chaves Amorim
  • Manoel Barros Bértolo
  • Paulo Louzada Júnior
  • Isabela Araújo Santos
  • Rina Dalva Neubarth Giorgi
  • Nathalia de Carvalho Sacilotto
  • Sebastião Cezar Radominski
  • Fernanda Maria Borghi
  • Maria Fernanda B Resende Guimarães
  • Maria Raquel da Costa Pinto
  • Gustavo Gomes Resende
  • Karina Rossi Bonfiglioli
  • Henrique Carriço da Silva
  • Maria de Fátima Lobato da Cunha Sauma
  • Marcel Lobato Sauma
  • Júlia Brito de Medeiros
  • Ivânio Alves Pereira
  • Gláucio Ricardo Wernwer de Castro
  • Claiton Viegas Brenol
  • Ricardo Machado Xavier
  • Licia Maria Henrique da Mota
  • Geraldo da Rocha Castelar Pinheiro

Abstract

The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment.The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA.In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed.A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed.Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.

Suggested Citation

  • Ana Paula Monteiro Gomides & Cleandro Pires de Albuquerque & Ana Beatriz Vargas Santos & Rodrigo Balbino Chaves Amorim & Manoel Barros Bértolo & Paulo Louzada Júnior & Isabela Araújo Santos & Rina Dal, 2019. "Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-7, March.
    • Handle: RePEc:plo:pone00:0213219
    DOI: 10.1371/journal.pone.0213219
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213219
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0213219&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0213219?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0213219. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.